MannKind outlines $110M-$120M 2026 Furoscix revenue target as ReadyFlow ships in weeks (NASDAQ:MNKD)
· seekingalpha.com
MannKind (MNKD) Q2 2026 earnings call recap: Afrezza pediatrics uptake, Furoscix ReadyFlow launch timing, revenue mix, cash, and risks—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...